Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
beta-adrenoreceptor antagonists	1865	42200-33-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nadolol corgard anabet solgol	A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor. Molecular weight: 309.41 Formula: C17H27NO4 CLOGP: 0.38 LIPINSKI: 0 HAC: 5 HDO: 4 TPSA: 81.95 ALOGS: -2.14 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nadolol
corgard
anabet
solgol

A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.

Molecular weight: 309.41
Formula: C17H27NO4
CLOGP: 0.38
LIPINSKI: 0
HAC: 5
HDO: 4
TPSA: 81.95
ALOGS: -2.14
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.16	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	2.25 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	73 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	34.58 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	30 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.90 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.14 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	9.20 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	-1.231		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.851		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	0.350	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	1.271	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	86.210	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	75.080	%	High	1
herg	hERG pIC50	4.202	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	1.309	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	3.105	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	91.170	%	High	1
kinase-safety-class	ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,IKBKB,ITK,JAK3,MAP2K6,MAP3K7,MAPK7,NTRK2,PDK2,PDK4,PIM2,PRKDC,SIK2,TEK,TGFBR1,ZAP70	31
kinase-selectivity-class	CDK4	1
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	1.633		High	1
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	1.086		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	2.239		High	1
mppb	Mouse plasma protein binding (% unbound)	90.060		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	0.982		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	92.140	%	High	1
rat-kpuu-brain	Rat brain Kpuu	0.007	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	0.908	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	89.700	%	High	1
rppb	Rat plasma protein binding (% unbound)	90.020	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	933.254	uM	High	1

Approvals:

Date	Agency	Company	Orphan
Dec. 10, 1979	FDA	KING PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	1331.41	17.67	418	15209	37552	90575268
Chronic sinusitis	559.30	17.67	194	15433	23608	90589212
Vaginal flatulence	462.31	17.67	144	15483	12494	90600326
Paraesthesia oral	445.17	17.67	177	15450	31482	90581338
Female genital tract fistula	440.48	17.67	151	15476	17717	90595103
Proctitis	435.62	17.67	144	15483	15115	90597705
Radiculopathy	427.58	17.67	149	15478	18356	90594464
Vaginal discharge	401.29	17.67	144	15483	19320	90593500
Procedural pain	375.28	17.67	159	15468	33201	90579619
Oral candidiasis	324.02	17.67	146	15481	35309	90577511
Rectal haemorrhage	306.82	17.67	186	15441	82558	90530262
Frequent bowel movements	277.66	17.67	153	15474	56782	90556038
Haematochezia	264.37	17.67	160	15467	70753	90542067
Colitis ulcerative	264.15	17.67	151	15476	60115	90552705
Weight decreased	253.57	17.67	319	15308	379591	90233229
Colitis	245.85	17.67	152	15475	69790	90543030
Dyspepsia	232.53	17.67	224	15403	197936	90414884
Therapeutic product effect incomplete	217.76	17.67	214	15413	193682	90419138
Drug ineffective	210.39	17.67	615	15012	1383683	89229137
Neovascularisation	209.42	17.67	50	15577	1580	90611240
Paradoxical drug reaction	146.96	17.67	50	15577	5716	90607104
Abdominal pain	145.24	17.67	251	15376	395470	90217350
Anaemia	116.77	17.67	214	15413	352588	90260232
Erythema	113.69	17.67	167	15460	229079	90383741
Constipation	109.52	17.67	183	15444	280212	90332608
Anuria	101.33	17.67	50	15577	14768	90598052
Extrapyramidal disorder	99.70	17.67	51	15576	16252	90596568
Infusion related reaction	73.01	17.67	196	15431	416584	90196236
Malaise	71.93	17.67	243	15384	585743	90027077
Drug ineffective for unapproved indication	66.28	17.67	69	15558	66575	90546245
Nausea	54.04	17.67	351	15276	1109965	89502855
Arthropathy	51.13	17.67	3	15624	366239	90246581
Systemic lupus erythematosus	47.52	17.67	4	15623	361892	90250928
Off label use	46.20	17.67	336	15291	1101916	89510904
Varices oesophageal	45.75	17.67	19	15608	3760	90609060
Synovitis	45.13	17.67	3	15624	329749	90283071
Pyrexia	44.57	17.67	228	15399	660257	89952563
Abdominal discomfort	40.24	17.67	16	15611	477312	90135508
Headache	37.21	17.67	265	15362	862481	89750339
Migraine	36.79	17.67	93	15534	190299	90422521
Contraindicated product administered	35.96	17.67	6	15621	320133	90292687
Hepatic enzyme increased	35.89	17.67	9	15618	360727	90252093
Hyperplastic cholecystopathy	31.61	17.67	7	15620	157	90612663
Joint swelling	30.79	17.67	25	15602	503275	90109545
Electrocardiogram QT prolonged	29.14	17.67	48	15579	72408	90540412
Alopecia	28.57	17.67	26	15601	495045	90117775
Hypersensitivity	28.55	17.67	22	15605	454655	90158165
Hepatic cirrhosis	28.31	17.67	44	15583	63209	90549611
Ligament sprain	28.22	17.67	22	15605	14577	90598243
General physical health deterioration	28.16	17.67	13	15614	355102	90257718
Ear congestion	27.73	17.67	13	15614	3429	90609391
Discomfort	26.98	17.67	7	15620	274328	90338492
Gastrointestinal disorder	26.32	17.67	6	15621	256681	90356139
Hypophosphataemia	25.76	17.67	21	15606	14833	90597987
Vomiting	25.43	17.67	62	15565	788231	89824589
Mobility decreased	25.43	17.67	6	15621	250728	90362092
Withdrawal syndrome	23.61	17.67	24	15603	22500	90590320
Stomatitis	23.47	17.67	9	15618	274689	90338131
Rash	23.10	17.67	66	15561	796034	89816786
Insulin-like growth factor increased	23.08	17.67	8	15619	966	90611854
Maternal exposure during pregnancy	21.86	17.67	18	15609	360045	90252775
Splenomegaly	21.84	17.67	18	15609	12906	90599914
Open reduction of fracture	21.70	17.67	8	15619	1154	90611666
Oligohydramnios	21.16	17.67	14	15613	7187	90605633
Impaired healing	21.15	17.67	7	15620	234192	90378628
Therapeutic product effect delayed	21.13	17.67	11	15616	3630	90609190
Pain	21.06	17.67	263	15364	996078	89616742
Blood cholesterol increased	21.05	17.67	5	15622	208007	90404813
Blister	20.73	17.67	9	15618	254989	90357831
Musculoskeletal stiffness	20.38	17.67	13	15614	296519	90316301
Electrocardiogram PR prolongation	20.05	17.67	7	15620	863	90611957
Hypertension	19.96	17.67	30	15597	457502	90155318
Rheumatoid factor positive	19.75	17.67	3	15624	171647	90441173
Ascites	19.70	17.67	32	15595	47708	90565112
Sleep disorder	19.57	17.67	5	15622	198025	90414795
Therapeutic product effect decreased	19.30	17.67	12	15615	277559	90335261
Irritable bowel syndrome	19.09	17.67	6	15621	207442	90405378
Intraventricular haemorrhage neonatal	18.41	17.67	5	15622	266	90612554
Hepatic cancer	18.12	17.67	11	15616	4870	90607950
Aortic arteriosclerosis	18.02	17.67	13	15614	7671	90605149
Swelling	17.78	17.67	28	15599	419030	90193790

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatic encephalopathy	98.25	16.90	45	5025	16397	42599868
Varices oesophageal	88.26	16.90	29	5041	4336	42611929
Hepatic cirrhosis	54.08	16.90	32	5038	19670	42596595
Ascites	51.17	16.90	47	5023	56631	42559634
Hepatic failure	45.33	16.90	37	5033	38063	42578202
Oesophageal varices haemorrhage	38.76	16.90	15	5055	3592	42612673
Portal hypertensive gastropathy	36.37	16.90	10	5060	813	42615452
Hypoglycaemia	36.27	16.90	40	5030	59814	42556451
Bradycardia	32.22	16.90	45	5025	85439	42530826
Lactic acidosis	28.72	16.90	31	5039	45230	42571035
Ammonia increased	28.59	16.90	13	5057	4646	42611619
Chronic hepatic failure	24.54	16.90	7	5063	651	42615614
Sinus arrest	23.29	16.90	9	5061	2147	42614118
Acute kidney injury	22.74	16.90	95	4975	367242	42249023
Liver transplant	18.07	16.90	8	5062	2683	42613582
Haemoglobin decreased	17.02	16.90	44	5026	132427	42483838

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Chronic sinusitis	544.17	16.41	191	18233	24893	110545982
Macular degeneration	485.44	16.41	169	18255	21490	110549385
Vaginal flatulence	468.48	16.41	143	18281	12001	110558874
Female genital tract fistula	453.09	16.41	150	18274	16369	110554506
Paraesthesia oral	433.45	16.41	175	18249	33496	110537379
Radiculopathy	426.09	16.41	149	18275	19187	110551688
Proctitis	421.79	16.41	143	18281	16784	110554091
Vaginal discharge	413.89	16.41	143	18281	17765	110553110
Procedural pain	367.33	16.41	158	18266	35407	110535468
Oral candidiasis	296.25	16.41	146	18278	44614	110526261
Rectal haemorrhage	263.38	16.41	192	18232	119641	110451234
Frequent bowel movements	250.27	16.41	153	18271	71237	110499638
Dyspepsia	247.97	16.41	225	18199	190740	110380135
Colitis ulcerative	243.94	16.41	155	18269	77208	110493667
Weight decreased	221.44	16.41	327	18097	467730	110103145
Haematochezia	213.68	16.41	167	18257	115357	110455518
Neovascularisation	207.96	16.41	50	18374	1687	110569188
Therapeutic product effect incomplete	201.60	16.41	216	18208	223589	110347286
Colitis	198.11	16.41	152	18272	102171	110468704
Abdominal pain	125.83	16.41	269	18155	512720	110058155
Paradoxical drug reaction	122.70	16.41	50	18374	9767	110561108
Varices oesophageal	108.50	16.41	42	18382	7173	110563702
Anaemia	99.23	16.41	255	18169	546831	110024044
Erythema	90.73	16.41	169	18255	291278	110279597
Infusion related reaction	90.02	16.41	197	18227	380965	110189910
Constipation	82.30	16.41	183	18241	357603	110213272
Anuria	82.24	16.41	51	18373	24290	110546585
Hepatic encephalopathy	77.68	16.41	52	18372	28204	110542671
Extrapyramidal disorder	71.94	16.41	50	18374	28817	110542058
Hepatic cirrhosis	63.80	16.41	67	18357	67559	110503316
Malaise	60.14	16.41	246	18178	671573	109899302
Ascites	57.42	16.41	74	18350	92734	110478141
Headache	53.91	16.41	289	18135	882088	109688787
Nausea	50.59	16.41	365	18059	1235325	109335550
Migraine	47.77	16.41	95	18329	171557	110399318
Oesophageal varices haemorrhage	44.62	16.41	20	18404	4925	110565950
Drug ineffective for unapproved indication	41.57	16.41	67	18357	102771	110468104
Drug ineffective	38.05	16.41	403	18021	1520137	109050738
Portal hypertensive gastropathy	35.57	16.41	13	18411	1895	110568980
Ammonia increased	34.94	16.41	20	18404	8230	110562645
Hypoglycaemia	34.41	16.41	66	18358	116038	110454837
Pyrexia	34.16	16.41	261	18163	898004	109672871
Arthropathy	34.02	16.41	4	18420	287518	110283357
Open reduction of fracture	33.04	16.41	8	18416	278	110570597
Hepatic failure	32.28	16.41	48	18376	68691	110502184
Pain	30.65	16.41	267	18157	954688	109616187
Hepatic enzyme increased	30.32	16.41	8	18416	320884	110249991
Hyperplastic cholecystopathy	29.40	16.41	7	18417	226	110570649
Ligament sprain	29.16	16.41	23	18401	16045	110554830
Systemic lupus erythematosus	28.97	16.41	4	18420	254334	110316541
Wound	28.39	16.41	3	18421	234434	110336441
Off label use	28.35	16.41	377	18047	1499808	109071067
Splenomegaly	28.11	16.41	27	18397	24471	110546404
Torsade de pointes	28.02	16.41	26	18398	22574	110548301
Ear congestion	27.37	16.41	13	18411	3652	110567223
Inability to afford medication	26.06	16.41	13	18411	4063	110566812
Gastrointestinal disorder	24.91	16.41	5	18419	241947	110328928
Hepatic cancer	24.74	16.41	18	18406	11138	110559737
Abdominal discomfort	24.40	16.41	18	18406	393840	110177035
Contraindicated product administered	23.81	16.41	6	18418	248261	110322614
Stomatitis	23.24	16.41	8	18416	270234	110300641
Portal vein thrombosis	21.86	16.41	14	18410	7044	110563831
Bradycardia	21.67	16.41	66	18358	155451	110415424
Febrile neutropenia	21.60	16.41	13	18411	316754	110254121
Neutropenia	20.87	16.41	19	18405	374601	110196274
Oligohydramnios	20.53	16.41	11	18413	3983	110566892
Electrocardiogram QT prolonged	19.87	16.41	51	18373	108909	110461966
Musculoskeletal stiffness	19.77	16.41	11	18413	279811	110291064
Joint swelling	19.70	16.41	27	18397	442818	110128057
Hypersensitivity	19.66	16.41	23	18401	403975	110166900
Lactic acidosis	19.64	16.41	46	18378	92765	110478110
Therapeutic product effect delayed	19.35	16.41	11	18413	4468	110566407
Intramedullary rod insertion	19.18	16.41	5	18419	235	110570640
Mobility decreased	18.80	16.41	8	18416	237414	110333461
Electrocardiogram PR prolongation	18.39	16.41	8	18416	1835	110569040
Hypoglycaemic unconsciousness	17.98	16.41	7	18417	1213	110569662
C-reactive protein increased	17.81	16.41	7	18417	217912	110352963
Vomiting	17.59	16.41	85	18339	910590	109660285
Gastrointestinal haemorrhage	17.50	16.41	64	18360	165454	110405421
Discomfort	17.37	16.41	7	18417	214700	110356175
Sinus arrest	17.21	16.41	10	18414	4232	110566643
Sleep disorder	16.87	16.41	6	18418	198638	110372237
Insulin-like growth factor increased	16.71	16.41	8	18416	2288	110568587
Maternal exposure during pregnancy	16.63	16.41	11	18413	254872	110316003
Gastric varices	16.43	16.41	6	18418	873	110570002

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C07AA12	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Beta blocking agents, non-selective
ATC	C07BA12	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS AND THIAZIDES Beta blocking agents, non-selective, and thiazides
FDA MoA	N0000000161	Adrenergic beta-Antagonists
FDA EPC	N0000175556	beta-Adrenergic Blocker
MeSH PA	D000319	Adrenergic beta-Antagonists
MeSH PA	D000889	Anti-Arrhythmia Agents
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D013565	Sympatholytics
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D018674	Adrenergic Antagonists
CHEBI has role	CHEBI:35530	β-adrenergic antagonist
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:35674	antihypertensive agent
CHEBI has role	CHEBI:38070	anti-arrhythmia drug
CHEBI has role	CHEBI:65023	anti-asthmatic agent
CHEBI has role	CHEBI:66991	sympatholytic agent

Related Drugs by ATC class:

C07AA Beta blocking agents, non-selective 13 drugs

alprenolol bopindolol bupranolol carteolol cloranolol mepindolol oxprenolol penbutolol pindolol propranolol sotalol tertatolol show all 13 →

C07BA Beta blocking agents, non-selective, and thiazides 5 drugs

metipranolol oxprenolol propranolol sotalol timolol

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Angina pectoris	indication	194828000
Thyrotoxicosis	off-label use	90739004	DOID:7997
Mitral valve prolapse	off-label use	409712001
Essential tremor	off-label use	609558009	DOID:4990
Prevention of Congenital Long QT Syndrome associated Ventricular Arrhythmia	off-label use
Myocardial Reinfarction Prevention	off-label use
Prevention of Bleeding Esophageal Varices	off-label use
Migraine Prevention	off-label use
Anuria	contraindication	2472002	DOID:2983
Bronchospasm	contraindication	4386001
Hypercholesterolemia	contraindication	13644009
Complete atrioventricular block	contraindication	27885002
Depressive disorder	contraindication	35489007
Hyperuricemia	contraindication	35885006	DOID:1920
Anaphylaxis	contraindication	39579001
Hypokalemia	contraindication	43339004
Sinus bradycardia	contraindication	49710005
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Sympathectomy	contraindication	57071006
Acute nephropathy	contraindication	58574008
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Hepatic coma	contraindication	72836002	DOID:12550
Diabetes mellitus	contraindication	73211009	DOID:9351
Oliguria	contraindication	83128009
Pulmonary emphysema	contraindication	87433001
Cardiogenic shock	contraindication	89138009
Hyponatremia	contraindication	89627008
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Hypomagnesemia	contraindication	190855004
Partial atrioventricular block	contraindication	195039008
Decompensated cardiac failure	contraindication	195111005
Acute pancreatitis	contraindication	197456007	DOID:2913
Disease of liver	contraindication	235856003	DOID:409
Raynaud's phenomenon	contraindication	266261006
Neonatal hyperbilirubinemia	contraindication	281610001
Pregnancy, function	contraindication	289908002
Severe chronic obstructive pulmonary disease	contraindication	313299006
Right ventricular failure	contraindication	367363000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.57	acidic
pKa2	9.31	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	ANTAGONIST	Ki	6.90	IUPHAR	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	ANTAGONIST	Ki	8.60	IUPHAR	CHEMBL
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN	ANTAGONIST	Ki	6.30	IUPHAR

External reference:

ID	Source
4017603	VUID
N0000145983	NUI
D00432	KEGG_DRUG
4017603	VANDF
C0027302	UMLSCUI
CHEBI:7444	CHEBI
CHEMBL521606	ChEMBL_ID
DB01203	DRUGBANK_ID
D009248	MESH_DESCRIPTOR_UI
39147	PUBCHEM_CID
554	IUPHAR_LIGAND_ID
3875	INN_ID
FEN504330V	UNII
151549	RXNORM
2018	MMSL
31	MMSL
5143	MMSL
d00018	MMSL
001854	NDDF
387482003	SNOMEDCT_US
82896009	SNOMEDCT_US
220045-89-6	SECONDARY_CAS_RN
FEN504330V	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Nadolol and Bendroflumethiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0115-5311	TABLET	40 mg	ORAL	ANDA	25 sections
Nadolol and Bendroflumethiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0115-5322	TABLET	80 mg	ORAL	ANDA	25 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	10135-686	TABLET	20 mg	ORAL	ANDA	19 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	10135-687	TABLET	40 mg	ORAL	ANDA	19 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	10135-688	TABLET	80 mg	ORAL	ANDA	19 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	21695-799	TABLET	40 mg	ORAL	ANDA	20 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	21695-800	TABLET	80 mg	ORAL	ANDA	20 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	21695-802	TABLET	20 mg	ORAL	ANDA	20 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	42254-094	TABLET	20 mg	ORAL	ANDA	15 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	42254-218	TABLET	40 mg	ORAL	ANDA	15 sections
NADOLOL	Human Prescription Drug Label	1	46708-402	TABLET	20 mg	ORAL	ANDA	17 sections
NADOLOL	Human Prescription Drug Label	1	46708-403	TABLET	40 mg	ORAL	ANDA	17 sections
NADOLOL	Human Prescription Drug Label	1	46708-404	TABLET	80 mg	ORAL	ANDA	17 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	50090-7995	TABLET	20 mg	ORAL	ANDA	19 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	51407-977	TABLET	20 mg	ORAL	ANDA	20 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	51407-978	TABLET	40 mg	ORAL	ANDA	20 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	51407-979	TABLET	80 mg	ORAL	ANDA	20 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	54868-3257	TABLET	40 mg	ORAL	ANDA	12 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	54868-3721	TABLET	80 mg	ORAL	ANDA	12 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5295	TABLET	20 mg	ORAL	ANDA	12 sections
Nadolol	Human Prescription Drug Label	1	59651-251	TABLET	40 mg	ORAL	ANDA	19 sections
Nadolol	Human Prescription Drug Label	1	59651-252	TABLET	80 mg	ORAL	ANDA	19 sections
Nadolol	Human Prescription Drug Label	1	59651-589	TABLET	20 mg	ORAL	ANDA	19 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	60687-302	TABLET	20 mg	ORAL	ANDA	18 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	60687-313	TABLET	40 mg	ORAL	ANDA	18 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	60687-887	TABLET	20 mg	ORAL	ANDA	20 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	60687-887	TABLET	20 mg	ORAL	ANDA	20 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	60687-898	TABLET	40 mg	ORAL	ANDA	20 sections
Nadolol	HUMAN PRESCRIPTION DRUG LABEL	1	60687-898	TABLET	40 mg	ORAL	ANDA	20 sections
NADOLOL	Human Prescription Drug Label	1	62332-402	TABLET	20 mg	ORAL	ANDA	17 sections

Ask DrugCentral

Try a sample question

nadolol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: